Editas (EDIT) To Report Q4 Earnings: What's In The Cards?
Zacks Investment Research | Feb 27, 2019 07:19AM ET
Editas Medicine, Inc. (NASDAQ:EDIT) is scheduled to report fourth-quarter and full-year 2018 results on February 28.
The company’s earnings history has been mixed so far, wherein it has surpassed the consensus estimates in two quarters while missing the same in two, recording average beat of 10.9%. In the last reported quarter, Editas delivered a positive earnings surprise of 55.56%.
Let’s see, how things are shaping up for the to-be-reported quarter.
Factors to Consider
Editas makes medicines to treat serious diseases using its proprietary genome editing platform based on CRISPR technology. Its lead pipeline candidate is EDIT-101 that uses CRISPR gene editing to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness. In November, the company announced FDA acceptance of its investigational new drug (“IND”) application to begin clinical studies for EDIT-101. It got a milestone payment from partner Allergan (NYSE:AGN) for IND acceptance which should be recognized as revenues in the fourth quarter.
Editas has a strategic alliance and an option agreement with Allergan under which the latter reserves its rights to license up to five of Editas’ genome editing ocular programs. In July 2018, Allergan exercised its option to develop and commercialize EDIT-101 globally while Editas exercised its right to a profit-sharing arrangement with Allergan under which it will co-develop and share equally in the profits and losses from EDIT-101 in the United States. Further, the company has the right to choose to co-develop and co-market another eye-disease program in the United States.
Editas is also pursuing the development of CRISPR candidates for eye diseases other than LCA10 including Usher Syndrome type 2A (USH2A) and the recurrent ocular Herpes Simplex Virus type 1 (HSV-1). Data from pre-clinical studies on these diseases has been positive. Editas also has CRISPR drugs in the pipeline to treat cancer, muscular dystrophy, alpha???1 antitrypsin deficiency and cystic fibrosis.
Moreover, the company has a collaboration and licensing deal with Juno Therapeutics, now part of Celgene (NASDAQ:CELG) , to use gene-editing approaches including CRISPR-Cas9 for developing engineered T cell medicines to treat cancer.
We expect management to provide more updates and detailed information on its pre-clinical studies during the upcoming conference call.
In January this year, Editas announced the resignation of Katrine Bosley from her role as president and CEO, effective Mar 1, 2019. Cynthia Collins has been appointed as interim CEO and should address the fourth quarter call. Meanwhile, Editas has initiated a search for a permanent CEO. We expect an update on the progress in this regard at the conference call.
Earnings Whispers
Our proven model does not conclusively show that Editas will beat on earnings this quarter. This is because a stock needs to have both a positive Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.